Li Zhang

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial

Jin‐Ji Yang, Caicun Zhou, Yi-Sheng Huang et al. · The Lancet Respiratory Medicine · 2017 · 183 citations

Neuro-oncology, Multiple Brain Metastases, Radiation Therapy +8

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Hongyun Zhao, Wenxiu Yao, Xuhong Min et al. · Journal of Thoracic Oncology · 2021 · 116 citations

Apatinib Plus Gefitinib, Medicine, Advanced Egfr-mutant Nsclc +8

Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients

Chi Wu, Huaijie Hao, Longyun Li et al. · Journal of Thoracic Oncology · 2009 · 102 citations · Full text

Tumor Biology, Cancer Detection, Medicine +10

Sex disparities in clinical characteristics and prognosis of immunoglobulin G4–related disease: a prospective study of 403 patients

Liwen Wang, Panpan Zhang, Xia Zhang et al. · Lara D. Veeken · 2018 · 99 citations